Chemistry:Remoxipride
 | |
| Clinical data | |
|---|---|
| Trade names | Roxiam |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 96%[1] |
| Protein binding | 89-98% |
| Metabolism | Hepatic[1] |
| Elimination half-life | 4-7 hours[1] |
| Excretion | Renal[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H23BrN2O3 |
| Molar mass | 371.275 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).[2] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.[2] Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.[3]
Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.[4] There was some interest in its use in the treatment of treatment-resistant schizophrenia.[5][6]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers". Psychopharmacology 98 (3): 304–9. 1989. doi:10.1007/bf00451679. PMID 2568653.
- ↑ 2.0 2.1 Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. 2007. ISBN 978-3-527-31058-6.
- ↑ "Biochemical pharmacology of the atypical neuroleptic remoxipride". Acta Psychiatrica Scandinavica. Supplementum 358: 27–36. 1990. doi:10.1111/j.1600-0447.1990.tb05282.x. PMID 1978484.
- ↑ "Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia". Journal of Psychopharmacology 7 (3): 276–82. January 1993. doi:10.1177/026988119300700307. PMID 22290842.
- ↑ "Remoxipride therapy in treatment resistant schizophrenia". Schizophrenia Research 9 (2–3): 235–236. April 1993. doi:10.1016/0920-9964(93)90521-J.
- ↑ "Remoxipride therapy in poorly responsive schizophrenics". Schizophrenia Research 4 (3): 316. April 1993. doi:10.1016/0920-9964(91)90208-9.
External links
 |  |
